SEC filing · 8-K

Viking Therapeutics, Inc.: Material agreement

Viking Therapeutics closed an equity offering and a convertible senior notes offering to raise capital for clinical programs.

Filed September 28, 2026

Positive for the company

What happened

The company sold 7,857,143 shares of common stock at $35.00 per share plus an additional 1,178,571 shares via full option exercise, generating net proceeds of approximately $297.0 million.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Viking Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.